LLY
Eli Lilly
Market cap$1.26T
Updated - ago
Eli Lilly (LLY) shares declined 5.57% to $1,353.90, reflecting a period of profit-taking and valuation digestion following a multi-week rally to new 52-week highs.1 Traders locked in gains despite robust Q3 revenue growth driven by strong demand for Mounjaro and Zepbound,2 as market participants scrutinized premium valuations and potential margin pressures.3
Eli Lilly and Company is a multinational pharmaceutical corporation headquartered in Indianapolis, Indiana, with roots tracing back to 1876. As one of the world's largest pharmaceutical manufacturers, Eli Lilly develops, produces, and markets a diverse portfolio of medications addressing major therapeutic areas including diabetes, oncology, immunology, cardiovascular disease, and neuroscience. The company is particularly renowned for its insulin products and innovative cancer treatments, serving patients and healthcare systems across more than 140 countries. Eli Lilly operates extensive research and development facilities dedicated to discovering new drug compounds and advancing existing therapies through clinical trials. The company maintains manufacturing operations globally to ensure reliable supply of its medications to hospitals, pharmacies, and healthcare providers worldwide. As a publicly traded corporation on the New York Stock Exchange, Eli Lilly's common stock represents fractional ownership in the company and its operations, making it a widely-held investment vehicle for those seeking exposure to the pharmaceutical and life sciences sector.